IMP1734
EIK1003-001 (IMP1734-101)
Phase 2 small_molecule active
Quick answer
IMP1734 for Advanced Solid Tumor is a Phase 2 program (small_molecule) at Eikon Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eikon Therapeutics
- Indication
- Advanced Solid Tumor
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active